Cargando…

Biological therapy for ulcerative colitis

Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Zubin, Shen, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423460/
https://www.ncbi.nlm.nih.gov/pubmed/25344680
http://dx.doi.org/10.1093/gastro/gou070
_version_ 1782370215158349824
author Arora, Zubin
Shen, Bo
author_facet Arora, Zubin
Shen, Bo
author_sort Arora, Zubin
collection PubMed
description Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC.
format Online
Article
Text
id pubmed-4423460
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44234602015-05-13 Biological therapy for ulcerative colitis Arora, Zubin Shen, Bo Gastroenterol Rep (Oxf) Reviews Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC. Oxford University Press 2015-05 2014-10-24 /pmc/articles/PMC4423460/ /pubmed/25344680 http://dx.doi.org/10.1093/gastro/gou070 Text en © The Author(s) 2014. Published by Oxford University Press and the Digestive Science Publishing Co. Limited. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Arora, Zubin
Shen, Bo
Biological therapy for ulcerative colitis
title Biological therapy for ulcerative colitis
title_full Biological therapy for ulcerative colitis
title_fullStr Biological therapy for ulcerative colitis
title_full_unstemmed Biological therapy for ulcerative colitis
title_short Biological therapy for ulcerative colitis
title_sort biological therapy for ulcerative colitis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423460/
https://www.ncbi.nlm.nih.gov/pubmed/25344680
http://dx.doi.org/10.1093/gastro/gou070
work_keys_str_mv AT arorazubin biologicaltherapyforulcerativecolitis
AT shenbo biologicaltherapyforulcerativecolitis